Skip to main content
Top
Published in: Intensive Care Medicine 8/2005

01-08-2005 | Experimental

Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin

Authors: Toshiaki Iba, Akio Kidokoro, Masaki Fukunaga, Kunihiko Nagakari, Masaru Suda, Seiichiro Yoshikawa, Yukiko Ida

Published in: Intensive Care Medicine | Issue 8/2005

Login to get access

Abstract

Objective

This study investigated the potential benefits of combination therapy using antithrombin (AT) with danaparoid sodium (DA) compared with the use of AT with unfractionated heparin (UFH) in the treatment of sepsis.

Methods

Rats infused with lipopolysaccharide were treated with either DA alone, AT alone, AT plus DA, AT plus UFH, or human serum albumin as controls. AT (125 U/kg) was injected into the AT group immediately after lipopolysaccharide infusion. The AT/DA and AT/UFH groups received the same dose of AT in conjunction with either DA (400 U/kg) or UFH (400 U/kg). The status of the mesenteric microcirculation was examined by intra-vital microscopy and the laboratory indices of coagulation, inflammation, and organ dysfunction were measured.

Results

The coagulation markers were improved following the administration of DA or UFH. The decreases in the WBC counts were significantly suppressed in the AT/DA group. The elevation of IL-6 decreased in the AT, DA, and AT/DA groups (all p<0.01) but not in the AT/UFH group. The prostaglandin I2 levels were significantly elevated only in the AT/DA group (p<0.05). The WBC adhesion was significantly suppressed in the DA, AT/UFH, and AT/DA groups (p<0.05), and the RBC velocity was best maintained in the AT/DA group with no associated increase in capillary hemorrhage. The elevation of ALT and BUN significantly improved only in the AT/DA group.

Conclusion

Organ dysfunction can thus be alleviated by even moderate doses of AT replacement when co-administered with DA.
Literature
1.
go back to reference Iba T, Kidokoro A, Yagi Y (1998) The role of the endothelium in changes in procoagulant activity. J Am Coll Surg 87:321–329 Iba T, Kidokoro A, Yagi Y (1998) The role of the endothelium in changes in procoagulant activity. J Am Coll Surg 87:321–329
2.
go back to reference Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R (2001) Proteinase-activated receptors. Pharmacol Rev 53:245–282PubMed Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R (2001) Proteinase-activated receptors. Pharmacol Rev 53:245–282PubMed
3.
go back to reference Freeman BD, Zehnbauer BA, Buchman TG (2003) A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20:5–9PubMed Freeman BD, Zehnbauer BA, Buchman TG (2003) A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20:5–9PubMed
4.
go back to reference Matthay MA (2001) Severe sepsis: a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med 344:759–762PubMed Matthay MA (2001) Severe sepsis: a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med 344:759–762PubMed
5.
go back to reference Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709CrossRefPubMed Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709CrossRefPubMed
6.
go back to reference Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, Holschermann H (2002) Antithrombin III inhibits nuclear factor k B activation in human monocytes and vascular endothelial cells. Blood 99:4015–4020PubMed Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, Holschermann H (2002) Antithrombin III inhibits nuclear factor k B activation in human monocytes and vascular endothelial cells. Blood 99:4015–4020PubMed
7.
go back to reference Iba T, Kidokoro A (2002) High dose antithrombin therapy for sepsis: mechanism of action. Shock 18:389–394PubMed Iba T, Kidokoro A (2002) High dose antithrombin therapy for sepsis: mechanism of action. Shock 18:389–394PubMed
8.
go back to reference Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group (2001) High-dose antithrombin III in severe sepsis. A randomized controlled trial. J Am Med Assoc 286:1869–1878 Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group (2001) High-dose antithrombin III in severe sepsis. A randomized controlled trial. J Am Med Assoc 286:1869–1878
9.
go back to reference Iba T, Kidokoro A (2004) What can we learn from the three mega-trials using anticoagulants in severe sepsis? Shock 22:508–512PubMed Iba T, Kidokoro A (2004) What can we learn from the three mega-trials using anticoagulants in severe sepsis? Shock 22:508–512PubMed
10.
go back to reference Dickneite G, Leithauser (1999) Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol 19:1566–1572PubMed Dickneite G, Leithauser (1999) Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol 19:1566–1572PubMed
11.
go back to reference Uchiba M, Okajima K, Murakami K (1998) Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 89:233–241PubMed Uchiba M, Okajima K, Murakami K (1998) Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 89:233–241PubMed
12.
go back to reference Danhof M, de Boer A, Magnani HN, Stiekema JC (1992) Pharmacokinetic considerations on orgaran (ORG10172) therapy. Haemostasis 22:73–78PubMed Danhof M, de Boer A, Magnani HN, Stiekema JC (1992) Pharmacokinetic considerations on orgaran (ORG10172) therapy. Haemostasis 22:73–78PubMed
13.
go back to reference Iba T, Kidokoro S, Fukunaga M, Ogasawara T, Kato H (2004) Antithrombin/danaparoid sodium combination therapy is effective for septic organ dysfunction. J Jpn Soc Intensive Care Med 11:193–199 Iba T, Kidokoro S, Fukunaga M, Ogasawara T, Kato H (2004) Antithrombin/danaparoid sodium combination therapy is effective for septic organ dysfunction. J Jpn Soc Intensive Care Med 11:193–199
14.
go back to reference Iba T, Kidokoro A, Fukunaga M, Fuse S, Suda M (2003) Antithrombin modulates the leukocyte-endothelial cell interaction in the staphylococcal enterotoxin B-challenged mouse. J Trauma 55:546–550PubMed Iba T, Kidokoro A, Fukunaga M, Fuse S, Suda M (2003) Antithrombin modulates the leukocyte-endothelial cell interaction in the staphylococcal enterotoxin B-challenged mouse. J Trauma 55:546–550PubMed
15.
go back to reference Wenzel RP (2003) Treating sepsis. N Engl J Med 347:966–967 Wenzel RP (2003) Treating sepsis. N Engl J Med 347:966–967
16.
go back to reference Bauer PR (2002) Microvascular responses to sepsis: clinical significance. Pathophysiology 8:141–148PubMed Bauer PR (2002) Microvascular responses to sepsis: clinical significance. Pathophysiology 8:141–148PubMed
17.
go back to reference Iba T, Kidokoro A, Fukunaga M, Fuse S, Suda M, Kunitada S, Hara T (2002) Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat. Shock 17:159–162PubMed Iba T, Kidokoro A, Fukunaga M, Fuse S, Suda M, Kunitada S, Hara T (2002) Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat. Shock 17:159–162PubMed
18.
go back to reference Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y (2005) Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. Crit Care Med 33:368–372PubMed Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y (2005) Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. Crit Care Med 33:368–372PubMed
19.
go back to reference Buller HR, ten Cate JW (1989) Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications and treatment with antithrombin III concentrate. Am J Med (Suppl 3B):44s–48s Buller HR, ten Cate JW (1989) Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications and treatment with antithrombin III concentrate. Am J Med (Suppl 3B):44s–48s
20.
go back to reference Meuleman DG (1992) Orgaran (Org10172): its pharmacological profile in experimental models. Haemostasis 22:58–65PubMed Meuleman DG (1992) Orgaran (Org10172): its pharmacological profile in experimental models. Haemostasis 22:58–65PubMed
21.
go back to reference Camerer E, Huang W, Coughlin SR (2000) Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 97:5255–5260PubMed Camerer E, Huang W, Coughlin SR (2000) Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 97:5255–5260PubMed
22.
go back to reference Kanke T, Macfarlane SR, Seatter MJ, Davenport E, Paul A, McKenzie RC, Plevin R (2001) Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory kappa B kinases in NCTC 2544 keratinocytes. J Biol Chem 276:31657–31666PubMed Kanke T, Macfarlane SR, Seatter MJ, Davenport E, Paul A, McKenzie RC, Plevin R (2001) Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory kappa B kinases in NCTC 2544 keratinocytes. J Biol Chem 276:31657–31666PubMed
23.
go back to reference Iba T, Kidokoro A, Fukunaga M, Ogasawara T, Kato H (2004) Antitirombin/danaparoid sodium combination therapy is effective for organ dysfunction induced by endotoxin. J Jpn Soc Intensive Care Med 11:193–199 Iba T, Kidokoro A, Fukunaga M, Ogasawara T, Kato H (2004) Antitirombin/danaparoid sodium combination therapy is effective for organ dysfunction induced by endotoxin. J Jpn Soc Intensive Care Med 11:193–199
24.
go back to reference Pulletz S, Lehmann C, Volk T, Schmutzler M, Ziemer S, Kox WJ, Scherer RU (2000) Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 28:2881–2886PubMed Pulletz S, Lehmann C, Volk T, Schmutzler M, Ziemer S, Kox WJ, Scherer RU (2000) Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 28:2881–2886PubMed
25.
go back to reference Yamauchi T, Umeda F, Inoguchi T, Nawata H (1989) Antithrombin III substitutes prostacyclin production by cultured aortic endothelial cell. Biochem Biophys Res Commun 163:1404–1411PubMed Yamauchi T, Umeda F, Inoguchi T, Nawata H (1989) Antithrombin III substitutes prostacyclin production by cultured aortic endothelial cell. Biochem Biophys Res Commun 163:1404–1411PubMed
26.
go back to reference Kozek-Langenecker SA, Spiss CK, Michalek-Sauberer A, Felfernig M, Zimpfer M (2003) Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. Crit Care Med 31:988–989PubMed Kozek-Langenecker SA, Spiss CK, Michalek-Sauberer A, Felfernig M, Zimpfer M (2003) Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. Crit Care Med 31:988–989PubMed
27.
go back to reference Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Kaneider NC, Dunzendorfer S, Wiedermann CJ, Romisch J, Schildberg FW, Menger MD (2002) Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 88:242–252PubMed Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Kaneider NC, Dunzendorfer S, Wiedermann CJ, Romisch J, Schildberg FW, Menger MD (2002) Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 88:242–252PubMed
28.
go back to reference Iba T, Kidokoro A, Fukunaga M (2001) Leukocyte and platelet adhesion induce microcirculatory disturbance in endotoxemic organ dysfunction. Jpn J Thromb Hemost 12:32–38 Iba T, Kidokoro A, Fukunaga M (2001) Leukocyte and platelet adhesion induce microcirculatory disturbance in endotoxemic organ dysfunction. Jpn J Thromb Hemost 12:32–38
29.
go back to reference Iba T, Kidokoro A, Fukunaga M (2003) The mechanism of thrombocytopenia during sepsis; from the site? of microcirculatory disturbance. J Jpn Biomed Forum 13:43–46 Iba T, Kidokoro A, Fukunaga M (2003) The mechanism of thrombocytopenia during sepsis; from the site? of microcirculatory disturbance. J Jpn Biomed Forum 13:43–46
30.
go back to reference Ley K, Cerrito M, Arfors KE (1991) Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules. Am J Physiol 260:H1667–H1673PubMed Ley K, Cerrito M, Arfors KE (1991) Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules. Am J Physiol 260:H1667–H1673PubMed
Metadata
Title
Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin
Authors
Toshiaki Iba
Akio Kidokoro
Masaki Fukunaga
Kunihiko Nagakari
Masaru Suda
Seiichiro Yoshikawa
Yukiko Ida
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 8/2005
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-005-2707-0

Other articles of this Issue 8/2005

Intensive Care Medicine 8/2005 Go to the issue

Physiological Note

Mechanisms of hypoxemia

Announcements

August 2005